Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. Show more

Location: Mailpoint 810, South Block, Southampton, SO16 6YD, United Kingdom | Website: https://www.synairgen.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

220.5K

52 Wk Range

$0.00 - $0.07

Previous Close

$0.00

Open

$0.00

Volume

N/A

Day Range

$0.00 - $0.00

Enterprise Value

-11.36M

Cash

4.554M

Avg Qtr Burn

-11.96M

Insider Ownership

0.57%

Institutional Own.

87.22%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SG016 / SNG001 Details COVID-19	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SNG001 (IFN-β) Details Skin disease/disorder, Psoriasis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.